



## Advanced Nuclear Medicine Ingredients (ANMI) SA transaction – Conference Call

Melbourne (Australia), Brussels and Liège (Belgium) – 26<sup>th</sup> November 2018. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), today announced that it has acquired Belgium-based Advanced Nuclear Medicine Ingredients (ANMI) SA. To facilitate shareholder queries, the Company will conduct an investor conference call as part of the transaction.

### Investor Conference Call

A conference call hosted by Telix CEO Dr Christian Behrenbruch, will be held at **9:00am AEDT on Friday 30 November 2018** to discuss the transaction. Participants can register for the conference call at the following link:

<https://services.choruscall.com.au/diamondpass/telixpharma-684982-invite.html>

You will receive a calendar notification with dial in details and a PIN for fast track access to the call. Alternative, participants may dial in using the details below at the scheduled time:

### Conference ID: 684 982

Australia Toll Free:	1 800 558 698
Alternate Australia Toll Free:	1 800 809 971
Australia Local:	02 9007 3187
New Zealand Toll Free:	0800 453 055
NZ Local (Auckland):	09 929 1687
NZ Local (Wellington):	04 974 7738
NZ Local (Christchurch):	03 974 2632
China Wide:	4001 200 659
Belgium:	0800 72 111
Canada:	1855 8811 339
France:	0800 913 848
Germany:	0800 182 7617
Hong Kong:	800 966 806
India:	0008 0010 08443
Indonesia:	001 803 019 3275
Ireland:	1800 948 625
Italy:	800 793 500
Japan:	0053 116 1281
Malaysia:	1800 816 294
Norway:	800 69 950
Philippines:	1800 1110 1462
Singapore:	800 101 2785
South Korea:	00 798 142 063 275
Sweden:	020 791 959
South Africa:	0800 999 976



Switzerland: 0800 820 030  
Taiwan: 008 0112 7397  
Thailand: 001800 156 206 3275  
UAE: 8000 3570 2705  
United Kingdom: 0800 051 8245  
United States: (855) 881 1339  
US Local (New York): (914) 202 3258  
US Local (Los Angeles): (909) 235 4020  
US Local (Chicago): (815) 373 2080

---

***Telix Corporate Contact***

Dr Christian Behrenbruch  
Telix Pharmaceuticals Limited  
CEO  
Email: [chris@telixpharma.com](mailto:chris@telixpharma.com)

***Telix Investor Relations (Australia)***

Arthur Chan  
WE Buchan  
Tel: +61 2 9237 2805  
Email: [arthurc@we-buchan.com](mailto:arthurc@we-buchan.com)

***Telix Investor Relations (US)***

Lisa Wilson  
In-Site Communications  
Tel: +1 212 452 2793  
Email: [lwilson@insitecony.com](mailto:lwilson@insitecony.com)

Important Information

*This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the products described in this release have obtained a marketing authorization in any jurisdiction, including the United States and Europe.*